Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib PK in Hepatic Impairment
NCT07282093Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olverembatinib in Chronic Myeloid Leukemia (CML), sponsored by Ascentage Pharma. Primary endpoints: Maximum observed plasma concentration, Time to Cmax and 6 more. Started Nov 2025; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT07282093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282093.